%PDF-1.4
%
43 0 obj
<>
endobj
40 0 obj
<>
endobj
197 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-24T16:44:56Z
2024-03-29T19:36:10-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T19:36:10-07:00
application/pdf
Heather
200809.may
uuid:3cf56428-1dd2-11b2-0a00-2009275d6100
uuid:3cf5642a-1dd2-11b2-0a00-aa0000000000
endstream
endobj
29 0 obj
<>
endobj
30 0 obj
<>
endobj
44 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
25 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
219 0 obj
[224 0 R]
endobj
220 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
/GS1 gs
465 777 92 -27 re
f*
BT
0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:5)Tj
0 Tw -46.2952 -0.0313 Td
(1120)Tj
/TT1 1 Tf
0.21291 Tw 10 0 0 10 54 713.1616 Tm
(vaccination is variable. Most cited cases of small vessel)Tj
0.0663 Tw 0 -1.2 TD
(vasculitis associated with recombinant hepatitis B vaccina-)Tj
0.02 Tc 0.36411 Tw T*
(tion have had favorable outcomes)Tj
0 Tw 6.5 0 0 6.5 209.9091 692.4615 Tm
(10-14,27)Tj
0.3463 Tw 10 0 0 10 234.2367 689.1616 Tm
[(. The )-18 (patient)]TJ
-0.00011 Tc 0.17371 Tw -18.0237 -1.2 Td
[(reported to have developed )18 (T)70 (akayasu\222)55 (s arteritis following)]TJ
0 Tc 0.08279 Tw T*
(plasma derived hepatitis B vaccination also improved)Tj
0 Tw 6.5 0 0 6.5 273.3439 668.4615 Tm
(16)Tj
-0.00011 Tc 0.0829 Tw 10 0 0 10 279.8438 665.1616 Tm
(. In)Tj
0 Tc 0.2747 Tw -22.5844 -1.2 Td
(contrast, our second patient had relentlessly progressive)Tj
0.18671 Tw T*
(disease despite a variety of immunosuppressive therapies)Tj
0.02499 Tw T*
(and eventually needed renal transplantation.)Tj
0.0965 Tw 1.2 -1.2 Td
[(Our cases indicate that lar)18 (ge artery vasculitis should be)]TJ
0.2818 Tw -1.2 -1.2 Td
(added to the list of rheumatic diseases that can follow)Tj
0.02499 Tw T*
(recombinant hepatitis B vaccination.)Tj
/TT2 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(REFERENCES)Tj
/TT1 1 Tf
0 Tc 0.02499 Tw 8 0 0 8 61 559.1616 Tm
[(1.)-875 (Carmeli )37 (Y)129 (, Oren R. Hepatitis B vaccination side ef)18 (fect. Lancet)]TJ
0 Tw 1.675 -1.25 Td
(1993;341:250-1.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875 (Gross K, Combe C, Kruger K, et al. )55 (Arthritis after hepatitis B)]TJ
0 Tc 1.675 -1.25 Td
(vaccination: report of three cases. Scand J Rheumatol 1995;)Tj
0 Tw 0 -1.25 TD
(24:50-2.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875 (Pope JE, Stevens )55 (A, Howson )18 (W)92 (, et al. )18 (The development of)]TJ
0 Tc 1.675 -1.25 Td
(rheumatoid arthritis after recombinant hepatitis B vaccination. )Tj
T*
(J Rheumatol 1998;25:1687-93.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875 (Soubrier M, Dubost JJ, Bielsa C, et al. Polyarthrite \351rosive)]TJ
0 Tc 1.675 -1.25 Td
(d\351clench\351e par une vaccination contre l\222h\351patite B [Erosive)Tj
T*
(polyarthritis following hepatitis B vaccination]. Presse M\351d)Tj
0 Tw T*
(1997;26:75.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875 (V)111 (autier G, Carty JE. )55 (Acute sero-positive rheumatoid arthritis)]TJ
0 Tc 1.675 -1.25 Td
(occurring after hepatitis B vaccination [letter]. Br J Rheumatol)Tj
0 Tw T*
(1994;33:991.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875 (Guiserix J. Systemic lupus erythematosis following hepatitis B)]TJ
0 Tc 1.675 -1.25 Td
(vaccine [letter]. Nephron 1996;74:441.)Tj
-1.675 -1.25 Td
[(7.)-875 (T)35 (udela P)111 (, Marti S, Bonal J. Systemic lupus erythematosus and)]TJ
1.675 -1.25 Td
(vaccination against hepatitis B [letter]. Nephron 1992;62:236.)Tj
-1.675 -1.25 Td
[(8.)-875 (Christian CL. Hepatitis B virus and systemic vasculitis. Clin Exp)]TJ
1.675 -1.25 Td
(Rheumatol 1991;9:1-2.)Tj
-1.675 -1.25 Td
[(9.)-875 (Cockwell P)111 (, )55 (Allen MB, Page R. )18 (V)111 (asculitis related to hepatitis B)]TJ
1.675 -1.25 Td
(vaccine [letter]. BMJ 1990;301:1281.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875 (Devin F)80 (, Roques G, Disdier P)111 (, Rodor F)80 (, )18 (W)80 (eiller PJ. Occlusion of)]TJ
0 Tc 2.175 -1.25 Td
(central retinal vein after hepatitis B vaccination [letter]. Lancet)Tj
0 Tw T*
(1996;347:1626.)Tj
0.0249 Tw -2.1381 -1.25 Td
[(1)37 (1.)-875 (Granel B, Disdier P)111 (, Devin F)80 (, et al. Occlusion de la veine centrale)]TJ
2.1381 -1.25 Td
(de la r\351tine apr\351s vaccination contre l\222h\351patite virale B pa\
r vaccin)Tj
T*
(recombinant. Quatre observations [Central retinal vein occlusion)Tj
T*
(after hepatitis B recombinant vaccination. 4 cases]. Presse M\351d)Tj
0 Tw T*
(1997;26:62-5.)Tj
0.02499 Tw 30.825 56.921 Td
[(12.)-875 (Kerleau JM, L\351svesque H, Lari G, et al. La vaccination contre)]TJ
2.175 -1.25 Td
(l\222h\351patite B est-elle une nouvelle cause de vascularite n\351crosa\
nte?)Tj
T*
([Is vaccination for hepatitis B a new cause for necrotizing)Tj
T*
(vasculitis?]. Rev M\351d Interne 1997;18:491-6.)Tj
-2.175 -1.25 Td
[(13.)-875 (Le Hello C, Cohen P)111 (, Bousser MG, et al. Suspected hepatitis B)]TJ
2.175 -1.25 Td
(vaccine related vasculitis. J Rheumatol 1999;26:191-4.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875 (Neau D, Laharie D, Zerbib F)80 (, et al. )18 (V)111 (ascularite grave apr\351s)]TJ
0 Tc 2.175 -1.25 Td
[(vaccination contre l\222h\351patite B: une observation [V)111 (asculitis after)]TJ
T*
(vaccination for hepatitis B]. Rev M\351d Interne 1996;17 Suppl 1:142.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875 (V)111 (anoli M, Gambrini D. )55 (A)-220 (case of Chur)18 (g-Strauss vasculitis after)]TJ
0 Tc 2.175 -1.25 Td
[(hepatitis B vaccination. )55 (Ann Rheum Dis 1998;57:256-7.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875 (Castrensa-Ilsa C, Herrera-Martinez G, )18 (V)111 (ega-Molina J. Erythema)]TJ
2.175 -1.25 Td
[(nodosum and )18 (T)70 (akayasu\222)55 (s arteritis after immunization with plasma-)]TJ
0 Tc T*
(derived hepatitis B vaccine. J Rheumatol 1993;20:1417-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875 (Dardik )55 (A, Ballermann BJ, )18 (W)40 (illiams GM. Successful delayed)]TJ
0 Tc 2.175 -1.25 Td
[(bilateral renal revascularization during active phase of )18 (T)70 (akayasu\222)55 (s)]TJ
-0.00011 Tc T*
[(arteritis. J )18 (V)111 (asc Sur)18 (g 1998;27:552-4.)]TJ
-2.175 -1.25 Td
[(18.)-875 (Lilic D, Ghosh SK. Liver dysfunction and DNA)-220 (antibodies after)]TJ
0 Tc 2.175 -1.25 Td
(hepatitis B vaccination. Lancet 1994;344:1292-3.)Tj
-2.175 -1.25 Td
[(19.)-875 (Fried M, Conen D, Conzelmann M, et al. Uveitis after hepatitis B)]TJ
2.175 -1.25 Td
(vaccination. Lancet 1987;2:631-2.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875 (Kerr GS, Hallhan CW)92 (, Giordano J, et al. )18 (T)70 (akayasu\222)55 (s arteritis. )55 (Ann)]TJ
0 Tc 2.175 -1.25 Td
(Intern Med 1994;120:919-29.)Tj
-2.175 -1.25 Td
[(21.)-875 (Brack )55 (A, Martinez-T)70 (aboada )18 (V)129 (, Stanson )55 (A, et al. Disease pattern in)]TJ
2.175 -1.25 Td
[(cranial and lar)18 (ge vessel giant cell arteritis. )55 (Arthritis Rheum)]TJ
0 Tw T*
[(1999;42:31)37 (1-7.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(22.)-875 (Hunder GG. Giant cell arteritis and polymyalgia rheumatica. Med)]TJ
2.175 -1.25 Td
[(Clin N )55 (Am 1997;81:195-217.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(23.)-875 (Luscher )18 (TF)80 (, Lie JT)74 (, Stanson )55 (A)80 (W)92 (, et al. )55 (Arterial fibromuscular)]TJ
0 Tc 2.175 -1.25 Td
(dysplasia. Mayo Clin Proc 1987;62:931-52.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(24.)-875 (Mader R, Narendran )55 (A, Lewtas J, et al. Systemic vasculitis)]TJ
0 Tc 2.175 -1.25 Td
(following influenza vaccination. Report of three cases and literature)Tj
T*
[(review)65 (. J Rheumatol 1993;20:1429-31.)]TJ
-2.175 -1.25 Td
[(25.)-875 (Bani-Sadr F)80 (, Guiet I, Humbert G. )18 (V)111 (asculitis related to hepatitis )55 (A)]TJ
2.175 -1.25 Td
(vaccination. Clin Infect Dis 1996;22:596.)Tj
-2.175 -1.25 Td
[(26.)-875 (Somer )18 (T)74 (, Finegold SM. )18 (V)111 (asculitides associated with infections,)]TJ
2.175 -1.25 Td
(immunizations, and antimicrobial drugs. Clin Infect Dis)Tj
0 Tw T*
(1995;20:1010-36.)Tj
0.02499 Tw -2.175 -1.25 Td
[(27.)-875 (Carmeli )37 (Y)129 (, DeMedina )18 (T)74 (. Serious hepatitis B vaccine adverse)]TJ
2.175 -1.25 Td
[(reactions, are they immune mediated? )18 (V)111 (accine 1993;1)37 (1:1358-9.)]TJ
-2.175 -1.25 Td
[(28.)-875 (Mathieu E, Fain O, Krivitsky )55 (A. Cryoglobulinemia after hepatitis B)]TJ
2.175 -1.25 Td
(vaccination [letter]. N Engl J Med 1996;335:355.)Tj
ET
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS1 CS 0 0 0 1 SCN
/GS1 gs
54 54 m
558 54 l
S
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS1 cs 0 0 0 0 scn
101.27 59.14 407.5 -10.83 re
f*
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS1 CS 0 0 0 1 SCN
0.5 w
101.27 59.14 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
108 0 obj
<>
endobj
203 0 obj
<>
endobj
46 0 obj
<>
endobj
51 0 obj
<>
endobj
56 0 obj
<>
endobj
55 0 obj
<>
endobj
73 0 obj
<>stream
HdVpT͋Ѡ,1$^AHAghb$35(B&ra:Vq2hEX_S
Z{w7=s?9?ޅ ;``UL?} !w^S[}Z inZ({|7ՖO
7uV>aB?w|%Ѽ'<\$#!bLsRC{fM˚<}~[be{nT`<9j,x::7YZ=uO$DE{x\cjC u}ǘHk4R܍x6ADb@(Ĥ+B#W=kTviч )
tc-vP k7m"-=X'%{MnJcrz>z6tD+̥F\fZ|Ot}0&`
ڎ`@&K1P!g݃3UՀ Oy#%@zWwwG
2 Ij؊QAж# ޑ<ɗ:YWU
^
E[q^8#8A<)I1
Vkk2j,D+tvSm1ILJ"H.VG9ƣƫf~
2eZ"9YWp9ak^d|o1P.' cIe^\ | 'RJ
&V^VS 3*M5f7]X{Yx]ū|S8W$BgW&eٌVO*F(I!Ay,}O9!dRصjZnS{Qcq,1̰UdM]Yy'w=Dd-9,c|F&cӜ作>!aUg9~X4y+$.mEc埒^8&>Oi`#Tavuazң^%|k\`L2W]fc'q}l5ͭV5j{?ZQD֘uO+uM~
9a/Ho뻥?fu]^ood
{)gjMll99)FMV瞴:N6>,̼'S)K(%/*y#
?sβLC cvM;X{֬ 2CqOV:?Sgfg`FkQۿOԓ~ j7~=z8@1_2w$95+ݱxٌP90i%}\F)1gdF0hv/E/
BT7;#ιe;TDǏ5v}a\TzH48*}W挴~i;H"tT&]Ҭ.q?w4V7;!{:;9~'qbv"`~QQ&T߷jzE2t^|J|iwCE'{6tMN?-4j|Y.qr)
FId8YI3Ayd! -\73Uo
5;yp39@N,UUxk/3a"qUqnM,%!8Qx+Ж}ZK,ִyYc5Fsd, unvP67a\m6ߨZY0>+i̯:Sų?1ڡgtV/yyԋ/cLigzP"um(&0bm7ygxJ7u.Ē~
bfVӮ")}vp7SXuI먞[ڝgTWmSsZDX^M[}3]ޤm;QmYԚ=3KGqݱ|w~YsƯ1:kIyKΎ1qm0!ƄG c[1 "Em(! JJi'U8i+6pkT43lt9pi j $y0K# 5`n gFvX4`Hg D#; h!hɋ
, g#q|$WHh"X4YiOuF#k[CyX!o-2P]MIyA
Ԇ